Melanoma, the most aggressive form of skin cancer with a high mutation rate, is the fifth most common cancer among Caucasians. Despite advancements in treatments like immune checkpoint inhibitors and targeted therapies, over 40% of patients experience immune-related adverse events, posing significant challenges. Neuropilin-1 (NRP1) has emerged as a critical immune-oncology target due to its overexpression in multiple cancers, where it enhances regulatory T cell (Treg) function and promotes tumour progression, often leading to a poor prognosis. This study explored the effects of NRP1 inhibition in B16-F10 melanoma and its impact on peripheral Treg-mediated immune responses. NRP1 was overexpressed in several cancers, including B16-F10 cells, compared to non-tumorigenic NIH-3T3 cells. It inhibited NRP1 selectively induced apoptosis in B16-F10 cells without affecting NIH-3T3 cells. It also reversed the immunosuppression of splenic T cells induced by B16-F10-conditioned supernatants in vitro by reducing suppressor T cell markers (NRP1, NKG2A, FOXP3), Treg activity, and secretion of immunomodulatory cytokines (IL-10, IL-17A). Additionally, NRP1 inhibition increased T cell proliferation and enhanced effector cytokine responses (TNF, IFN-γ, IL-6, IL-2). NRP1 inhibition also downregulated the STAT, ERK MAPK, and Smad2/3 pathways while upregulating the PI3K/AKT pathway. In splenic T cells isolated from B16-F10 tumour-bearing mice treated with an NRP1 inhibitor, there was a reduction in immunosuppressive T cell marker expression and Treg suppressive activity, alongside an increase in T cell proliferation. NRP1 inhibitor treatment also significantly reduced lung metastasis, decreased tumour volume, and improved survival rates in these mice. This study demonstrates that NRP1 inhibition may help reduce B16-F10 melanoma progression and associated peripheral Treg-mediated immunosuppression, highlighting its potential in developing future anti-cancer immunotherapy strategies, particularly in combination therapies.